I don't recall saying anything about RAC undertaking an RC110 trial?
I don't think RAC can afford to run an AML/EML trial and an mBC trial (or a trial targeting another indication(s) looking to demonstrate Zan's FTO/CP properties - perhaps basket doxo synergy??) with the $20m they have on hand. We want trials in multiple indications commencing as soon as the RC220 patent is lodged.
Shareholders are unhappy because they think there is no catalyst for rerate until RC220 trial results. I think that is incorrect. Buyers enter on the promise of upside. BP jointly funding one of our development program does just that.
The best value for shareholder money is some sort of joint development program in a niche indication like AML - and we just received the results to pursue this. It won't validate RC220 in patients near term but it will validate the broader commercial opportunity with Zan, without the cost of dilution.
Again, IMO the next catalyst for a SP rerate won't be new trial results*, it will be a material agreement.
*The company may be sitting on top secret FTO/CP data from Sheba 2.0.
Ann: RC220 Meets Quality Specifications, page-85
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |